Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin

International Journal of Oncology

Volumn 32, Issue 4, 2008, Pages 931-936

  Song, Ju Han ^a,b   Kim, Seung Hyun ^a,b   Kim, Hyeoung Joon ^b   Hwang, Seung Yong ^c   Kim, Tae Sung ^a,b  

^a Korea University   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

ABC transporter; Acute myeloid leukemia; Apoptosis; Drug resistance; Indomethacin

Indexed keywords

ABC TRANSPORTER; CASPASE 3; CASPASE 8; CYTARABINE; IDARUBICIN; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN 1; ABCA3 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME; DRUG EFFECT; DRUG RESISTANCE; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CYTARABINE; DRUG RESISTANCE, NEOPLASM; HUMANS; IDARUBICIN; INDOMETHACIN; LEUKEMIA, MYELOID, ACUTE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHENOTYPE;

EID: 44449120041     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.4.931     Document Type: Article

References (31)

1. Tallman MS, Gilliland DG and Rowe JM: Drug therapy for acute mycloid leukemia. Blood 106: 1154-1163, 2005.
2. Newland A: Progress in the treatment of acute myeloid leukaemia in adults. Int J Hematol 76: 253-258, 2002.
3. Styczynski J: Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol 8: 59-75, 2007.
4. Van der Kolk DM, De Vries EG, Müller M and Vellenga E: The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 43: 685-701, 2002.
5. Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5: 30, 2005.
6. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, et al: P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 18: 1837-1844, 2000.
7. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, et al: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85: 186-193, 1995.
8. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F and Sauerbrey A: BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16: 1443-1447, 2002.
9. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F and Sauerbrey A: Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 9: 1083-1086, 2003.
10. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, De Longueville F, et al: ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 12: 4357-4363, 2006.
11. Tourneur L, Dellue S, Lévy V, Valensi F, Radford-Weiss I, Legrand O, Vargaftig J, et al: Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res 64: 8101-8108, 2004.
12. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
13. Smith BD, Bambach BJ, Vala MS, Barber JP, Enger C, Brodsky RA, Burke PJ, et al: Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br J Haematol 102: 1042-1049, 1998.
14. Olsson A, Norberg M, Okvist A, Derkow K, Choudhury A, Tobin G, Celsing F, et al: Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. Br J Cancer 97: 769-777, 2007.
15. Inaba H, Shimada K, Zhou YW, Ido M, Buck S, Yonehara S, Kaplan J, et al: Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1. Int J Oncol 27: 573-579, 2005.
16. Zhang G, Tu C, Zhang G, Zhou G and Zheng W: Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk Res 24: 385-392, 2000.
17. Lion JY, Ghelani D, Yeh S and Wu KK: Non-steroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res 67: 3185-3191, 2007.
18. Song JH, Choi CH, Yeom HJ, Hwang SY and Kim TS: Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis. Life Sci 79: 193-202, 2006.
19. Lee DH, Park T and Kim HW: Induction of apoptosis by disturbing mitochondrial-membrane potential and cleaving PARP in Jurkat T cells through treatment with acetoxyscirpenol mycotoxins. Biol Pharm Bull 29: 648-654, 2006.
20. Park J, Kim SH, Cho D and Kim TS: Formononetin, a phytooestrogen, and its metabolites up-regulate interleukin-4 production in activated T cells via increased AP-1 DNA binding activity. Immunology 116: 71-81, 2005.
21. Rojewski MT, Körper S, Thiel E and Schrezenmeier H: Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines. Chem Res Toxicol 17: 119-128, 2004.
22. Kishimoto Y, Sampi K, Kuraishi Y, Takemoto Y, Okabe K, Tamura K, Mizoguchi H, et al: A phase II study employing combination regimens containing KRN8602 in drug-resistant acute myeloid leukemia and acute lymphoblastic leukemia. KRN8602 Leukemia Study Group. Anticancer Drugs 10: 267-273, 1999.
23. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O and Marie JP: Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRPL Leukemia 18: 1246-1251, 2004.
24. Van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, et al: The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106: 2646-2654, 2005.
25. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993.
26. Sinicrope FA, Pazdur R and Levin B: Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma. Clin Cancer Res 2: 37-41, 1996.
27. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, et al: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflanimatory drugs (NSAIDs). Eur J Cancer 34: 1250-1259, 1998.
28. Matsunaga S, Asano T, Tsutsuda-Asano A and Fukunaga Y: Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1). Cancer Chemother Pharmacol 58: 348-353, 2006.
29. Norwood K, Wang RY, Hirschmann-Jax C, Andreeff M, Brenner MK, Goodell MA and Wulf GG: An in vivo propagated human acute mycloid leukemia expressing ABCA3. Leuk Res 28: 295-299, 2004.
30. Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, Griesinger F and Trümper L: ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 89: 1395-1397, 2004.
31. Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D, Montserrat E, et al: Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 92: 1406-1414, 1998.